References
- World Health OrganizationReducing risks, promoting healthy life 2002 [cited 2008 July 30] http://www.who.int/whr/2002/en/whr02_en.pdfAccessed August 6, 2009
- KannelWBBlood pressure as a cardiovascular risk factor: prevention and treatmentJAMA1996275157115768622248
- ChobanianAVBakrisGLBlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003 2892560257212748199
- ManciaGDe BackerGDominiczakA2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens2007251105118717563527
- BirkenhagerWHde LeeuwPWNon-peptide angiotensin type 1 receptor antagonists in the treatment of hypertensionJ Hypertens19991787388110419059
- BallKJWilliamsPAStumpeKORelative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensivesJ Hypertens Suppl2001 19S49S5611451215
- BrunnerHRArakawaKAntihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goalsClin Drug Investig200626185193
- BrunnerHRLaeisPClinical efficacy of olmesartan medoxomilJ Hypertens Suppl200321S43S4612929907
- GilesTDOparilSSilfaniTNComparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertensionJ Clin Hypertens (Greenwich)2007918719517341994
- OparilSWilliamsDChrysantSGComparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertensionJ Clin Hypertens (Greenwich)20013283291, 31811588406
- NeutelJMClinical studies of CS-866, the newest angiotensin II receptor antagonistAm J Cardiol20018737C43C
- PüchlerKLaiesPStumpeKOBlood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonistJ Hypertens Suppl200119s41s48
- SellinLStegbauerJLaeisPAdding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertensionJ Hypertens2005232083209216208152
- BarriosVBoccanelliAEwaldSEfficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST studyClin Drug Investig200727 545558
- KjeldsenSOsIH⊘ieggenAFixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazideAm J Cardiovasc Drugs20055172215631534
- ChrysantSWeberMWangAEvaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazideAm J Hypertens20041725225915001200
- BarriosVEscobarCOlmesartan medoxomil plus hydrochlorothiazide for treating hypertensionExpert Opin Pharmacother2008912913618076344
- RumpLAmbrosioniEBurnierMInitial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertensionJ Hum Hypertens20062029930116452995
- WagstaffAJValsartan/hydrochlorothiazide: a review of its use in the management of hypertensionDrugs2006661881190117040120
- WeirMRCrikelairNLevyDEvaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertensionJ Clin Hypertens (Greenwich)2007910311217268215
- NeutelJMSmithDHWeberMAUse of an olmesartan medoxomil-based treatment algorithm for hypertension controlJ Clin Hypertens (Greenwich)2004616817415073470
- BarriosVBanegasJRRuilopeLMEvolution of blood pressure control in SpainJ Hypertens2007251975197717762665
- BarriosVEscobarCCalderonABlood pressure and lipid goal attainment in the hypertensive population in the primary care setting in SpainJ Clin Hypertens (Greenwich)2007932432917485967
- Wolf-MaierKCooperRSKramerHHypertension treatment and control in five European countries, Canada, and the United StatesHypertension200443101714638619